Skip to main content

Biotech startups from the Basel Area confirm leading position

| News

Biotech startups from the Basel Area confirm leading position

10.09.2021

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also include several startups based in the Basel Area, mainly from the biotech sector. The Medtech firm Resistell even made it into the top ten, seven others are among the Top 100.

The 11th edition of the TOP 100 Swiss Startup Award was celebrated in Schlieren (img: evenito)

Venturelab has once again been busy handing out the TOP 100 Swiss Startup Awards. The rankings contain several startups from the Basel Area, with the Medtech company Resistell even making the lofty heights of the top ten firms. Based in Muttenz in the canton of Basel-Landschaft, Resistell has developed a particularly rapid test against antibiotic resistance and secured ninth place in the rankings.

The second-highest ranking from the Basel Area went to Tolremo Therapeutics AG (17th place). Likewise headquartered in Muttenz, this biotech firm is developing cancer therapies for precision medicine applications. It was also supported by BaseLaunch, the startup accelerator and incubator of the investment and innovation promotion agency Basel Area Business & Innovation.

Perseo Pharma AG, again based in Muttenz, registered a major improvement on the previous year, jumping from 60th place to 31st place. This makes it the third-highest ranked company from the Basel Area in the rankings. It develops therapeutic enzymes for the treatment of cancers and rare genetic diseases.

In addition, other Basel Area firms to make the rankings include Versameb (54th place), Alentis Therapeutics (57th place), Synendos Therapeutics (72th place) and Scailyte (98th place). Both Versameb and Alentis Therapeutics are headquartered at the Technologiepark Basel and received support from BaseLaunch. The former develops therapies on the basis of mRNA sequencing, while the latter develops molecules to treat advanced hepatic and renal fibrosis. Synendos Therapeutics, based at the Switzerland Innovation Park Basel Area in Allschwil in the canton of Basel-Landschaft, also received support from BaseLaunch and is working on an approach that aims to treat anxiety, mood and stress-related disorders. For its part, Scailyte is developing a software solution to detect diseases. The company was supported by Basel Area Business & Innovation during the process of establishing its headquarters at the Novartis Campus of the Switzerland Innovation Park Basel Area.

Due to the fact that only companies founded no longer than five years ago are considered for the TOP 100 Swiss Startup Awards, Venturelab has also produced a scale-up list. This table serves to honor startups founded between five and ten years ago, with companies from the Basel Area represented here too. These include the biotechnology firms Crispr Therapeutics AGPolyneuron Pharmaceuticals AG and T3 Pharmaceuticals AG. The latter two companies were also supported by BaseLaunch. In addition, Synendos Therapeutics AG was also named as the winner of a public vote award.

The eleventh edition of the TOP 100 Swiss Startup Award was organized by Venturelab and supported by Credit Suisse and the Swiss Venture Club. On this occasion, the award ceremony took place in the new startup space in Schlieren. The best startups are afforded an opportunity to present their businesses to a group of international investors. Among other aspects, these startups will benefit from reporting in several languages – including Chinese and Japanese.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.